Hemostemix arranges payment plans for VesCell treatment

Executive Summary

• Hemostemix Inc. has established a patient financing partnership with MedLoanFinancing to facilitate monthly payment plans for its VesCell (ACP-01) treatments in Florida, aiming to expand patient access and generate predictable revenue.
• The company is actively presenting clinical trial results to podiatry and cardiology clinics in Naples and Boca Raton, reporting significant clinical and business interest.
• VesCell is an autologous stem cell therapy approved under Florida law for life-threatening or severely debilitating conditions where standard care has been exhausted, with recent peer-reviewed data highlighting potential benefits for brain-computer interface performance and cardiovascular health.

Key Details

• Financing Structure: Partnership with MedLoanFinancing to offer monthly payment plans for VesCell treatments.
• Credit Limits: Patients can obtain up to $50,000 of credit to purchase a treatment, which includes physician expenses.
• Strategic Rationale: CEO Thomas Smeenk and CCO Croom Lawrence state that this facility is expected to be preferred by 80% of patients, making the therapy more affordable (comparable to a monthly car payment) and providing predictable revenue to fund operations.
• Clinical Outreach: The team is presenting clinically relevant results to podiatry and cardiology clinics in Naples and Boca Raton this week.
• Regulatory Context: Florida law authorizes advanced cell therapies like VesCell for patients with life-threatening or severely debilitating conditions who have exhausted standard-of-care options.
• Scientific Foundation: A peer-reviewed article in Cells (June 29, 2025) details how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis, and synaptic plasticity.
• Clinical History: Hemostemix has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications.
• Phase II Results (CLTI): The Phase II trial for Chronic Limb-Threatening Ischemia (CLTI) was published in the Journal of Biomedical Research & Environmental Science. Midpoint results presented to the 41st meeting of vascular surgeons by the University of British Columbia and University of Toronto showed:
  • 0% mortality (compared to a 50% five-year mortality rate in the general CLTI population).
  • Cessation of pain.
  • Wound healing in 83% of patients followed for up to 4.5 years.
• Indications: ACP-01 is reported as safe and clinically relevant for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina.

Notable Quotes

• "MedLoanFinancing provides individuals with an easy to digest monthly payment plan, to obtain a VesCell treatment," stated Thomas Smeenk. "Equivalent to a monthly car payment, an individual can obtain up to $50,000 of credit to purchase a treatment, including any physician expenses. This greatly expands access to VesCell for patients in need."
• "This payment plan facility is how 80 per cent of patients will prefer to gain access to our care," stated Croom Lawrence, chief commercial officer. "Like a monthly car payment, it makes VesCell more affordable and generates predictable revenue to fund company operations."